Novartis to build another plant in the United States

Due to high demand for its radiopharmaceutical for the treatment of tumors of neuroendocrine Lutter (Lutathera), the company and Novartis will build a second plant in the U.S., says FiercePharma.

When in 2017, Novartis has acquired the French company Advanced Accelerator Applications (AAA) for 3.9 billion dollars, no one could have predicted that the demand for a new drug of Lettera intended for the treatment of neuroendocrine tumors exceed the forecasts of analysts. A new plant in Indianapolis will work in 2023, the cost of the platform is not disclosed.

Lutter is a radiopharmaceutical that binds to somatostatin receptors on tumor cells, and then the drug enters the cell, targetirovanie exerting a destructive effect of radiation. A drug approved for the treatment of inoperable somatostatin-receptor positive neuroendocrine tumors of the gastrointestinal tract or the pancreas.

In 2019, sales of the drug exceeded Luttera 441 million dollars, net sales increased by 31% over the fourth quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]